Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Myeloproliferative Disorders
NCT02210858Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2000
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in myeloproliferative disorder (MPD), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), sponsored by National Cancer Institute. Started May 2000; status: completed.
02
Drugs
tipifarnib
03
Conditions
myeloproliferative disorder (MPD)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02210858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210858.